ArriVent BioPharma
AVBP
83 hedge funds and large institutions have $539M invested in ArriVent BioPharma in 2025 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 29 increasing their positions, 22 reducing their positions, and 11 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 22
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
4% more funds holding
Funds holding: 80 → 83 (+3)
1% more ownership
Funds ownership: 84.47% → 85.46% (+1%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
29% less capital invested
Capital invested by funds: $757M → $539M (-$218M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Infinitum Asset Management
Fort Lauderdale,
Florida
|
+$10.3M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$8.6M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.17M |
| 4 |
Millennium Management
New York
|
+$2.58M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$2.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$15.6M |
| 2 |
Goldman Sachs
New York
|
-$3.19M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.13M |
| 4 |
Morgan Stanley
New York
|
-$652K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$548K |
AVBP Hedge Fund Activity: Q1 2025 in Review
83 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q1 2025, worth a combined $539M — down 29% from $757M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AVBP positions and 11 closed out — a net gain of 3 holders — while 29 added to existing stakes and 22 trimmed.
The largest buyer was Infinitum Asset Management, adding an estimated $10.3M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $15.6M sold.
- 83 institutional investors held ArriVent BioPharma (AVBP) as of Q1 2025, up from 80 in Q4 2024.
- Funds reported $539M of ArriVent BioPharma stock for Q1 2025, down 29% quarter-over-quarter.
- 14 funds opened new ArriVent BioPharma positions in Q1 2025 and 11 closed out, a net change of +3 holders.
- The largest ArriVent BioPharma buyer in Q1 2025 was Infinitum Asset Management, an estimated $10.3M added.
- The largest ArriVent BioPharma seller in Q1 2025 was Cormorant Asset Management, an estimated $15.6M sold.
Based on aggregated 13F filings for Q1 2025.